Prospect Park Capital Corp. announced that its board of directors has appointed Seymour H. Fein, M.D. as a director to replace Frank Mancuso who is focusing on other ventures. Dr. Fein's professional activities have been focused on drug development research for over 35 years.

He has been extensively involved in the successful development of numerous drugs, biologics and medical devices over this time leading to FDA approvals for over 20 drugs (NDAs, sNDAs, BLAs) and devices (PMAs). Dr. Fein has served as a member of the Board of Directors of development stage biotechnology and pharmaceutical companies.